Spark Therapeutics goes public - Technical.ly Philly

Business

Jan. 30, 2015 2:22 pm

Spark Therapeutics goes public

The Children's Hospital of Philadelphia, whose research the company is based on, owns more than half of the company's shares.

Spark Therapeutics works out of the University City Science Center's 3737 Market Street building.

(Photo by Juliana Reyes)

Spark Therapeutics went public on NASDAQ today, and the Children’s Hospital of Philadelphia is one big winner.

The startup, based on a decade’s worth of research at CHOP, raised $161 million with its initial public offering, pricing 7 million shares at $23 each. But then, the share price ballooned to $43, raising the company’s value to nearly $1 billion, according to an Inquirer report. That made the 4.9 million shares owned by CHOP — that’s 53.44 percent of the Spark shares — worth as much as $220 million. (Obviously, this could fluctuate.) CHOP committed $50 million in the fall of 2013 when the company was formed. CHOP CEO Steven Altschuler is chairman of Spark’s board.

Spark Therapeutics is a pre-revenue company that aims to cure rare genetic diseases like types of hemophilia and blindness. Its ticker symbol is “ONCE,” referring to the company’s aim of curing, not just treating, these diseases, the Inquirer reported.

Spark raised a $72.8 million Series B led by Silicon Valley investors Sofinnova Ventures last year, and its 50 employees work out of a 28,000-square-foot office at the University City Science Center’s new 3737 Market Street building.

“Our foundation as a company has been born of the work done in West Philadelphia,” CEO Jeff Marrazzo said last fall at the 3737 Market Street ribbon-cutting. “We want to be an example of a company that can not only have its past here but also its future.”

Marrazzo (the son of WHYY CEO Bill Marrazzo) owns 380,000 shares of the company, now worth around $16 million, the Inquirer reported.

Advertisement

Spark’s IPO came on the same day as Shake Shack’s, but it garnered much less media attention, despite raising more money and being potentially more world-changing, Fortune noted.

-30-
LEAVE A COMMENT

Advertisement

More unicorns might finally IPO in 2018

BioBots rebrands as Allevi in a push for the software space

What to make of the SEC’s rule change on confidential IPOs

SPONSORED

Philly

Vistar Media’s tech stack is not for the faint-of-heart

Chesterbrook

Deacom

Inside Sales Representative

Apply Now
Center City, Philadelphia

IntegriChain

Senior Business Analyst

Apply Now
Philadelphia, PA

IntegriChain

Senior Data Engineer

Apply Now

How can Philly help its life sciences startups ‘bridge the gap’?

Former US Senate candidate Katie McGinty has entered the VC world

BioBots moves HQ, staff of 10 to Pennovation Center

SPONSORED

Philly

MakeOffices’ new location is ripe for startup collaborations

Chesterbrook, PA

Deacom

Enterprise Software Sales Representative

Apply Now
Philadelphia

Azavea

Software Engineer, Geospatial Insights Team

Apply Now
Philadelphia

Clarivate Analytics

Senior UI Developer

Apply Now

Sign-up for regular updates from Technical.ly

Do NOT follow this link or you will be banned from the site!